Enjoy complimentary customisation on priority with our Enterprise License!
The global tumor ablation market size is estimated to grow by USD 1.43 billion, at a CAGR of 14.62% between 2023 and 2028.
Minimally invasive tumor ablation techniques like radiofrequency, microwave, cryoablation, and HIFU offer less invasive options compared to traditional surgery, reducing morbidity and mortality rates. These procedures entail shorter hospital stays, faster recovery, and less postoperative pain, enhancing patient satisfaction. For example, AngioDynamics Inc. provides advanced systems like StarBurst RFA and Solero Microwave Ablation System. Moreover, minimally invasive techniques target tumors precisely while preserving surrounding tissues and organ function, crucial for complex or critical areas. This preservation enhances patient outcomes and quality of life, driving demand for such procedures. The rising preference for minimally invasive oncological interventions, with benefits like reduced morbidity and faster recovery, fuels the growth of the market.
To learn more about this report, Download Report Sample
The market share growth by the radiofrequency ablation segment will be significant during the forecast period. Radiofrequency ablation (RFA) is a minimally invasive procedure used to destroy cancer cells by delivering radiofrequency pulses through a needle electrode inserted into the tumor. Patients prefer RFA for its shorter hospital stays, faster recovery, and reduced complications compared to open surgery.
Get a glance at the market contribution of various segments Download PDF Sample
The radiofrequency ablation segment was valued at USD 455.26 million in 2018. Further, radiofrequency ablations (RFAs) are effective for treating various tumors like liver, lung, kidney, and bone metastases, often achieving complete tumor elimination and improved outcomes. RFA also provides effective pain relief by destroying nerve endings within tumors, benefiting patients with cancer-related pain. Innovations like Boston Scientific's RF3000 system enhance RFA's precision and safety, offering single-needle electrodes and advanced generator controls. These advancements expand RFA's applicability, driving the growth of the market during the forecast period.
The liver cancer?segment will account for the largest share of this segment.? Liver tumor ablation, used for treating HCC and liver metastases, offers a minimally invasive alternative to surgery. Through techniques like radiofrequency, microwave, or cryoablation, energy is delivered to destroy tumors while preserving healthy liver tissue. This method, repeatable if needed, extends patient survival and manages cancer progression. With growing global liver cancer rates, advanced technologies like TechsoMed's BioTraceIO, FDA-cleared in January 2024, further drive demand for liver tumor procedures. Hence, such factors are fuelling the growth of this segment during the forecast period.
The lung cancer segment is also showing steady growth in the market. Tumor ablation provides a minimally invasive option for treating early-stage lung tumors, including primary and metastatic cancers. It's particularly beneficial for patients who can't undergo surgery due to tumor location or lung conditions. Besides curative intent, it offers palliative relief for advanced lung cancer symptoms. With the global rise in lung cancer cases, innovations like Medtronic's ILLUMISITE platform enhance treatment accuracy, driving demand for lung tumor ablation procedures and aiding the market's growth during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The increasing incidence of cancer, including liver, lung, and renal cancer, fuels the demand for tumor ablation procedures in North America. With aging populations and prevalent risk factors like obesity and smoking, the cancer burden grows, expanding the patient pool for ablation treatments. Favorable reimbursement policies and rising healthcare expenditure in North America further support procedure adoption. For example, in Canada, healthcare spending rose by 2.8% in 2023 to USD 344 billion, representing 12.2% of the GDP. Medtronic's recent FDA clearance for its OsteoCool 2.0 bone tumor ablation system enhances treatment options, offering advanced features like simultaneous probe use and increased power, driving market growth in the region.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market forecasting report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Alpinion Medical Systems Co. Ltd., Apyx Medical Corp., Bioventus LLC, Boston Scientific Corp., BVM Medical Ltd., EDAP TMS, ForTec Medical, IceCure Medical Ltd., Johnson and Johnson Services Inc., Medtronic Plc, Merit Medical Systems Inc., Mermaid Medical Group, Monteris Medical Corp., Olympus Europa SE and Co. KG, Profound Medical Corp., Smith and Nephew plc, Stryker Corp., TechsoMed Medical Technologies Ltd., Terumo Corp., and Varian Medical Systems Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market exhibits lucrative growth potential driven by factors such as precision medicine initiatives and increasing public funding for cancer control. With a rising geriatric population, there's a demand for minimally invasive therapies like ablative surgeries, which offer cost containment measures. Surgeons utilize precision tools like catheters and sensors for clinical application in surgical procedures, enhancing healthcare cost effectiveness while improving patient protection and affordable care through the mode of treatment advancements. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
Rising focus on cancer treatment in outpatient settings is the key factor driving the market. Outpatient tumor ablation procedures offer cost-effective alternatives to inpatient treatments, reducing facility fees and overhead costs. Conducted in ambulatory surgery centers (ASCs) or clinics, these procedures provide convenience and accessibility for patients, especially those needing multiple sessions or facing transportation challenges. Patients can return home shortly after the procedure, promoting faster recovery and improved comfort.
For instance, Merit Medical Systems Inc.'s STAR tumor ablation System employs targeted RadioFrequency Ablation (t-RFA) to treat metastatic spinal tumors in outpatient settings. Additionally, outpatient settings lower the risk of hospital-acquired infections, benefiting immunocompromised patients. This shift toward outpatient care aligns with value-based and patient-centered approaches, driving the growth of the market by enhancing patient satisfaction and optimizing healthcare delivery during the forecast period.
Increasing adoption of image-guided tumor ablation is the primary trend shaping the market. Image-guided tumor ablation techniques, such as ultrasound, CT, MRI, and fluoroscopy, offer real-time visualization of tumors and surrounding tissues, ensuring precise targeting and minimal damage to healthy tissue. This real-time monitoring allows physicians to adjust the procedure as needed, enhancing safety and efficacy. Integration with navigation systems and software platforms further improves precision and workflow efficiency.
Additionally, these techniques enable customized treatment planning based on tumor characteristics, optimizing outcomes and reducing recurrence risk. The growing adoption of image-guided ablation in oncology is driven by its accuracy, patient safety, reduced procedure time, and personalized treatment options. This trend is expected to fuel the growth of the market by enhancing treatment efficacy and patient outcomes during the forecast period.
High upfront costs of devices and procedures is the major challenge that affects the market growth. Healthcare providers may hesitate to adopt or expand their programs due to budgetary constraints and concerns about the returns on investment (ROI). Additionally, the high upfront costs of procuring devices and equipment, facility upgrades, and training initiatives must be weighed against potential revenue streams and reimbursement rates to ensure sustainable operations. Besides, patients may face out-of-pocket expenses for co-payments, deductibles, and other related costs, potentially leading to disparities in access to innovative cancer treatments.
.Furthermore, reimbursement policies and rates for tumor ablation procedures vary across healthcare systems and payers, impacting the financial feasibility of offering these services. Healthcare providers may face challenges in securing adequate reimbursements to cover the high upfront costs of equipment acquisition, procedure-related expenses, and ongoing operational costs. Thus, the high upfront costs associated with tumor ablation devices and procedures are expected to slow down the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
The market is witnessing a surge in innovation, with techniques like microwave ablation (MWA), high-intensity focused ultrasound, and laser ablation emerging as effective energy sources for targeting tumor cells. These methods, along with advancements in medical equipment such as ablation probes and ultrasound systems, enable minimally invasive surgeries with reduced incisions and tissue damage. Techniques like internally cooled radiofrequency probes and cooled radiofrequency denervation further enhance pain management while minimizing blood loss.
Further, technologies like MRI systems and monitoring systems ensure precise targeting of solid tumors within various organs, offering improved outcomes for patients across different cancer types including ENT cancer and bone metastasis. With growing Cancer screening rates and advancements in image-guided equipment, the market continues to expand to meet the needs of a diverse cancer patient population. The market holds lucrative growth potential with a focus on minimally invasive therapies and cost containment measures in cancer control initiatives. Surgeons employ ablative surgeries and utilize advanced devices like electrodes, catheters, and sensors for precise clinical application. Patients benefit from these procedures, experiencing shorter recovery times and reduced healthcare costs. This market evolution aligns with the global purchasing power parity, ensuring broader accessibility to effective mode of treatment options for cancer patients.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
180 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 14.62% |
|
Market Growth 2024-2028 |
USD 1.43 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
14.42 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 44% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Alpinion Medical Systems Co. Ltd., AngioDynamics Inc., Apyx Medical Corp., Bioventus LLC, Boston Scientific Corp., BVM Medical Ltd., EDAP TMS, ForTec Medical, IceCure Medical Ltd., Johnson and Johnson Services Inc., Medtronic Plc, Merit Medical Systems Inc., Mermaid Medical Group, Monteris Medical Corp., Olympus Europa SE and Co. KG, Profound Medical Corp., Smith and Nephew plc, Stryker Corp., TechsoMed Medical Technologies Ltd., Terumo Corp., and Varian Medical Systems Inc. |
|
Market dynamics |
Parent market analysis, market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
